4/17/2009 | SS | Gilead Sciences completes $20-per-share buyout of CV Therapeutics
|
4/15/2009 | SS | Gilead Sciences to buy 88% of CV Therapeutics' shares in tender offer
|
3/31/2009 | SS | Gilead Sciences, CV Therapeutics merger closer to completion
|
3/18/2009 | SS | CV Therapeutics' board in favor of merger with Gilead Sciences
|
3/16/2009 | SS | Astellas Pharma drops bid for CV Therapeutics
|
3/16/2009 | SS | Market Commentary: Agrium may increase CF Industries bid; CV Therapeutics, Gilead face few regulatory concerns
|
3/13/2009 | CV | Market Commentary: Johnson Controls, Bank of America, Nasdaq, GM gain with stocks; CV Therapeutics quiets, holds firm
|
3/13/2009 | SS | Market Commentary: Market unsure of CV Therapeutics bidding war; Roche to close on Genentech before month's end
|
3/12/2009 | SS | Gilead agrees to acquire CV Therapeutics for $20 per share
|
3/12/2009 | SS | Market Commentary: Genentech OKs latest bid; bidding war on way for CV Therapeutics; CF Industries pushes for Terra deal
|
3/12/2009 | CV | Gilead to assume $292 million in CV Therapeutics' convertible debt
|
3/12/2009 | CV | Market Commentary: CV Therapeutics higher, Gilead slips on merger news; Johnson Controls convertibles move upward
|
3/12/2009 | SS | CV Therapeutics board rejects Astellas Pharma tender offer
|
2/27/2009 | SS | Astellas Pharma begins tender offer for CV Therapeutics, files lawsuit against company
|
2/27/2009 | SS | Market Commentary: Astellas takes CV offer hostile; Agrium considered stronger suitor in bid for CF Industries
|
2/25/2009 | CV | CV Therapeutics reduces amount of convertibles outstanding by $107.3 million in 2008
|
2/25/2009 | SS | Market Commentary: Terra bid moot on Agrium's offer for CF Industries; Senate comments continue for Live Nation merger
|
2/20/2009 | SS | CV Therapeutics again turns down offer from Astellas Pharma
|
2/20/2009 | SS | Market Commentary: Rohm and Haas investors list Dow's options; CV Therapeutics rejects Astellas bid; GM shares plummet
|
2/2/2009 | SS | Market Commentary: Second Amylin shareholder wants changes; analysts predict higher bid for CV Therapeutics
|
1/28/2009 | SS | CV Therapeutics turns down Astellas Pharma for second time
|
1/28/2009 | SS | Citigroup drops stake to 6.3% in CV Therapeutics
|
1/28/2009 | SS | Market Commentary: CV Therapeutics could open door to higher bid; CF Industries considers options after Terra says no
|
1/27/2009 | CV | Market Commentary: CV Therapeutics jumps on bid; Bank of America, Citigroup gain amid rumors; Newmont launches deal
|
1/27/2009 | SS | Astellas Pharma seeks to acquire CV Therapeutics
|
1/27/2009 | SS | Market Commentary: Roche bid for Genentech predicted to increase; CV not likely to bite at Astellas offer, analyst says
|
1/16/2009 | CV | CV Therapeutics retired more than $100 million of convertibles in 2008
|
11/6/2008 | CV | CV Therapeutics repurchases $14.9 million of its convertibles
|
7/31/2008 | CV | CV Therapeutics repurchases $53 million in convertible subordinated notes
|
4/16/2008 | CV | Market Commentary: Little moved amid stock gains; Countrywide, CV gain, Kinetic Concepts falls below par; Huntington prices
|
2/29/2008 | SS | Third Point reduces stake in CV Therapeutics to 2.1%
|
7/30/2007 | SS | CV Therapeutics to seek alternatives with help of Frederick Frank
|
7/30/2007 | SS | Market Commentary: Verizon Wireless goes country; Ingersoll-Rand sells Bobcat to Korean firm; Foot Locker, CV need help
|
7/30/2007 | SS | Market Commentary: Verizon Wireless goes country; Ingersoll-Rand sells Bobcat to Korean firm; Foot Locker, CV need help
|
5/17/2007 | SS | Third Point reports 9.9% stake in CV Therapeutics
|
5/16/2007 | CV | Market Commentary: Bausch & Lomb gains on buyout; CV Therapeutics keeps rising; Countrywide, Micron launch giant deals
|
3/27/2007 | CV | Market Commentary: CV Therapeutics, AtheroGenics gain on data; Equinix higher, Kilroy quiet in gray
|
3/26/2007 | CV | Market Commentary: CV Therapeutics drops on downgrade; Freeport-McMoran leads new deals; Nortel, SL Green, Vornado slip
|
3/7/2007 | CV | Market Commentary: CV Therapeutics, Conseco fall with stocks; Barnes gains on debut; Cypress up, Developers quiet in gray
|
2/23/2007 | CV | Reaping lessons from Wild Oats: Market value-based make-whole feature caps protection, says Lehman
|
11/1/2006 | BT | CV Therapeutics rated at neutral by Merrill
|
10/31/2006 | BT | CV Therapeutics reports $62.7 million net loss for quarter, ends with $373.3 million cash, equivalents
|
9/26/2006 | BT | CV completes Merlin Timi-36 study
|
8/22/2006 | BT | CV Therapeutics at neutral by Merrill
|
8/18/2006 | BT | CV Therapeutics greenshoe fully exercised for 1.35 million shares
|
8/16/2006 | BT | New Issue: CV Therapeutics raises $85.5 million in upsized follow-on of 9 million shares at $9.50 each
|
8/16/2006 | BT | Market Commentary: CV Therapeutics gains after pricing follow-on; Acadia adds again; Accentia slides
|
8/14/2006 | BT | Market Commentary: CV Therapeutics falls 10%; Dendreon rises; Biomira up; Neurochem higher by 23.5%
|
8/14/2006 | CV | Market Commentary: CV Therapeutics gets hit; Ford gains on upgrade; Calgon borrow uncertain; Tanger climbs further
|
8/14/2006 | BT | CV Therapeutics plans follow-on offering of 7.5 million shares via Lehman, Merrill
|
8/4/2006 | BT | CV Therapeutics rated at neutral by Merrill
|
8/4/2006 | BT | Market Commentary: Invitrogen, CV Therapeutics plunge; Osiris debuts higher, ends steady; Adolor gets eyed
|
7/12/2006 | BT | Market Commentary: Genzyme, Genentech 2Q results counteract; Curis retraces losses; Antigenics, CV, Cell Genesys up
|
7/7/2006 | BT | Market Commentary: LifeCell lower; CV Therapeutics loses 2%; Indevus up; Tercica off by 8%; Amarillo Biosciences off
|
7/7/2006 | BT | CV Therapeutics: Safety board says Ranexa angina study can continue as planned
|
6/22/2006 | BT | CV Therapeutics acquires rights to ranolazine in Asia
|
6/19/2006 | BT | CV Therapeutics says Ranexa reduces angina frequency
|
6/12/2006 | BT | PTC Therapeutics, CV Therapeutics sign license arrangement
|
6/12/2006 | BT | Market Commentary: NPS Pharma drops 19% to new low; Avigen up; CV Therapeutics drops 5%; Pozen pushed up 11%
|
6/7/2006 | BT | CV Therapeutics completes Regadenoson trial enrollment
|
5/25/2006 | BT | CV Therapeutics completes enrollment of Ranexa study in acute coronary syndromes
|
5/23/2006 | CV | Market Commentary: Cameron debut hurt by premium; Global Crossing deal sees poor borrow; CBIZ prices offer within talk
|
5/12/2006 | BTCV | New Issue: Merrill Lynch prices $15 million 3% capped appreciation notes linked to biotech stock basket
|
4/26/2006 | BT | CV Therapeutics stays at neutral by Merrill
|
4/25/2006 | BT | CV Therapeutics reports first-quarter loss of $70.5 million
|
4/20/2006 | PP | Market Commentary: Jumping oil prices will likely spark energy offerings, sellsiders say; O2Diesel prices two PIPEs
|
4/19/2006 | PP | Market Commentary: Discovery Labs procures $50 million equity line; Alteon plans $2.5 million unit sale
|
4/18/2006 | BT | Market Commentary: Gilead pitching jumbo convertible; CV Therapeutics bags $200 million; Labopharm deal emerges; Nabi up
|
4/18/2006 | PP | Market Commentary: CV Therapeutics secures $200 million equity line; Scolr Pharma prepares to wrap $11.85 million stock sale
|
4/18/2006 | BTPP | New Issue: CV Therapeutics obtains $200 million equity line
|
4/18/2006 | BT | CV Therapeutics files $200 million stock shelf
|
3/13/2006 | BT | Bear Stearns on CV Therapeutics: peer perform
|
3/13/2006 | BT | Market Commentary: NitroMed off on data; NPS gains 7%; Vasogen falls on trial failure; Medicines up 10%; Myriad higher
|
3/10/2006 | BT | CV Therapeutics begins shipping angina drug Ranexa to wholesalers
|
3/10/2006 | BT | Market Commentary: Insmed, Corautus off on deals; NPS Pharma gains, dives on FDA; CV Therapeutics higher; Kos up
|
3/2/2006 | BT | Merrill puts CV Therapeutics at neutral
|
3/2/2006 | BT | Market Commentary: Genentech recoups from Avastin blow; ImClone slumps; Nastech drops; NitroMed strikes new low
|
2/9/2006 | BT | CV Therapeutics continues Ranexa study as planned based on interim analysis
|
1/30/2006 | CV | Market Commentary: Omnicare converts plunge on raid news; new DRS issue slows down; GMAC bids lift GM
|
1/30/2006 | BT | Merrill lowers CV to neutral
|
1/30/2006 | BT | Market Commentary: Theravance at bat; Amylin dives; Nektar reverses; CV Therapeutics takes a hit; First Horizon higher
|
1/27/2006 | BT | FDA approves CV Therapeutics' Ranexa for chronic angina
|
1/20/2006 | BT | Market Commentary: DOR BioPharma stock jumps 15.6% on orBec news, equity line; Shire, Impax settle patent suit
|
1/20/2006 | CV | Market Commentary: Hutchinson hovers around par; Schlumberger surges; Ford sags, Oscient tumbles
|
1/19/2006 | BT | Market Commentary: Endo Pharmaceuticals prices $417.75 million secondary stock sale; Procyon to merge with Cellpep
|
1/19/2006 | CV | Market Commentary: Advanced Micro, Cypress gain, but Intel weaker; Hutchinson prices upsized $225 million deal
|
11/16/2005 | BT | CV Therapeutics reports study shows Ranexa cuts angina frequency
|
10/26/2005 | BT | Merrill rates CV Therapeutics at buy
|
10/26/2005 | BT | Market Commentary: NxStage talk sweetened; Predix pulls IPO; Biosite plunges; CV Therapeutics dives; Idenix rises
|
10/25/2005 | BT | CV Therapeutics withdraws European application for ranolazine, to resubmit
|
10/20/2005 | BT | CV Therapeutics' stent coating may improve performance of drug-coated stents
|
10/17/2005 | BT | CV Therapeutics given buy rating by Merrill
|
8/24/2005 | BT | CV Therapeutics reiterated by Merrill at buy
|
8/11/2005 | BT | CV Therapeutics kept by Merrill at buy
|
8/9/2005 | BT | CV Therapeutics estimates cut by Merrill
|
7/28/2005 | BT | CV Therapeutics kept by Merrill at buy
|
7/28/2005 | BT | Market Commentary: Advanced Life Sciences IPO cut; ZymoGenetics plans follow-on; Elan plunges on credit worries
|
7/22/2005 | BT | CV Therapeutics initiated by Merrill at buy
|
7/22/2005 | CV | Market Commentary: Cheniere deal, earnings boost convertible market's energy names; biotech eases slightly
|
7/15/2005 | CV | Market Commentary: Chiron drops as convertibles market trades mostly flat to lower; but CV Therapeutics, Isis gain
|
7/13/2005 | BTCV | CV Therapeutics calls $79.65 million 4.75% convertibles
|
7/13/2005 | CV | Market Commentary: Advanced Medical's new issue jumps, spurring overall market; Continental rebounds, Liberty Media mixed
|
7/7/2005 | BT | CV Therapeutics greenshoe exercised in full, lifting stock issue to $180.36 million
|
7/7/2005 | CV | Market Commentary: Biotechs up as convertibles find footing after early dip; airlines down; some oil and gas names extend gains
|
7/6/2005 | CV | Market Commentary: Cooper Cameron, Halliburton rise as oil prices surge; Schering-Plough eases, but LSI gains
|
7/1/2005 | BTCV | CV Therapeutics greenshoe exercised in full, raising 3.25% convertibles offer to $149.5 million
|
7/1/2005 | CV | Market Commentary: Brocade convertibles lift on default notice; market activity quiets ahead of holiday weekend
|
6/29/2005 | BT | New Issue: CV Therapeutics sells $130 million convertibles at 3.25%, up 25%, 7.3 million shares at $21.60
|
6/29/2005 | BT | Market Commentary: CV Therapeutics, Lonza upsize convertibles, both higher in trade; Millennium gains on new CEO
|
6/29/2005 | CV | New Issue: CV Therapeutics upsized $130 million convertibles yield 3.25%, up 25%
|
6/29/2005 | CV | Market Commentary: CV Therapeutics' new deal gains, supporting biotechs; Mirant trades in heavy volume; General Mills eases
|
6/28/2005 | BT | Market Commentary: Lonza, CV Therapeutics converts on tap; Cubist zooms; Abgenix up on belt tightening; Wyeth a boost
|
6/27/2005 | BT | Market Commentary: CV Therapeutics quiet in gray, Impax Labs refinances converts; Nitromed off; Ligand moves up
|
6/27/2005 | CV | Market Commentary: Lear eases on layoffs; airlines dive on oil spike; Weatherford watched as put nears; CV, Impax deals eyed
|
6/23/2005 | BT | Market Commentary: Forest Labs up sharply; King sees buying; Avalon sets IPO range; Salix dives; Xoma, ViaCell bounce
|
6/23/2005 | CV | Market Commentary: Convertibles market trades mostly lower, but some energy issues climb with oil prices
|
6/22/2005 | BTCV | CV Therapeutics plans to buy back up to $79.6 million 4.75% convertibles with new deal proceeds
|
6/22/2005 | BT | Market Commentary: HemoSense cuts IPO range again; CV Therapeutics offerings emerge; Eyetech zooms on boosted outlook
|
6/22/2005 | CV | Market Commentary: CV Therapeutics, Evergreen Solar launch after quiet day; Reckson deal upsized, reoffered in thin trade
|
6/22/2005 | BTCV | CV Therapeutics to price $100 million convertibles talked at 3.25%-3.75%, up 20%-25%
|
2/8/2005 | PP | Market Commentary: Private placement volume remains weak; Breaker Energy plans C$13.16 million offering
|
2/7/2005 | PP | Market Commentary: Private placement volume stalls on lower stocks; China Yuchai plans $25 million deal
|
2/4/2005 | PP | New Issue: CV Therapeutics raises $25 million in direct placement
|
2/4/2005 | PP | Market Commentary: Private placements remain strong as stocks, oil rise; CV Therapeutics raises $25 million
|
12/23/2004 | PP | New Issue: CV Therapeutics raises $20 million in direct placement of stock
|
8/9/2004 | CV | CV Therapeutics buybacks of 4.75% convertibles now total $116.6 million
|
6/8/2004 | CV | CV Therapeutics greenshoe exercised, raising convertibles to $150 million
|
6/3/2004 | CV | Market Commentary: Beazer hangs around par; Phelps Dodge dividend crushes hedgers; CV Therapeutics up on drug news
|
5/14/2004 | CV | CV Therapeutics brings buybacks of 43/4% convertibles to $101.6 million
|
5/13/2004 | CV | New Issue: CV Therapeutics upsized $125 million convertible yields 2.75%, up 27.5%
|
5/13/2004 | CV | Market Commentary: CV Therapeutics, Pixelworks both trade below par out of gate; Tower Auto deal piques interest
|
5/12/2004 | CV | Market Commentary: CV Therapeutics bid at 100.375 in gray market; Pixelworks still; OSI Pharma, ImClone up sharply
|
5/11/2004 | CV | CV Therapeutics $100 million convertible talked at 23/4%-31/4%, up 25%-30%
|
5/11/2004 | CV | Market Commentary: Electronic Data Systems active on potential dividend cut and equity issuance
|
12/18/2003 | CV | Deutsche analyst: CV Therapeutics convertibles should fare well despite drug setback
|
10/17/2003 | CV | Market Commentary: XL holds up against stock slide on warning, boost to reserves; new Getronics euro issue zooms
|
6/13/2003 | CV | New Issue: CV Therapeutics $100 million convertibles yield 2.0%, up 34%
|
6/12/2003 | CV | CV Therapeutics $100 million convertibles talked to yield 1.5-2.0%, up 34-38%
|
6/12/2003 | CV | Market Commentary: Yield-grabbers reach for busted convertibles, distressed issues; new paper mixed in secondary
|
4/10/2002 | CV | JPMorgan recommends 9 biotech convertibles for yield, capital appreciation, relative value
|
11/14/2001 | CV | Market Commentary: Convertible market slows in flat session; CV Therapeutics soars
|
11/13/2001 | CV | Merrill Lynch says CV Therapeutics poised to pop, convert attractive for hedge or outright investors
|